PDF factsheet

angiogenesis inhibitors in advanced breast cancer (metastatic) for all type of patients, clinical trials results

bevacizumab + capecitabine versus capecitabine
AVF2119g (Miller) cape, 2005	capecitabine + bevacizumab 15 mg/kg iv every 3 weeks versus capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks	patients with metastatic breast cancer previously treated with an anthracycline and a taxane	open US
RIBBON-I (Robert) on top capecitabine, 2009	Capecitabine + bevacizumab 15 mg/kg iv every 3 weeks versus capecitabine (Cape; 2,000 mg/m(2) for 14 days),	irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer	double-blind
bevacizumab + docetaxel versus docetaxel
AVADO (Miles) 7.5mg, 2010	bevacizumab 7.5mg/kg every 3 weeks plus docetaxel versus placebo plus docetaxel	first-line treatment of HER2-negative metastatic breast cancer	double-blind
AVADO (Miles) 15mg , 2009	Docetaxel + bevacizumab 7.5 mg/kg iv every 3 weeks versus	first-line treatment of HER2-negative metastatic breast cancer
bevacizumab + endocrine therapy versus endocrine therapy
LEA,	bevacizumab + letrozole/fulvestrant versus letrozole or fulvestrant	first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -negative and hormone receptor-positive advanced breast cancer
bevacizumab + methotrexate versus methotrexate
Burstein, 2005	Methotrexate + cyclophosphamide + bevacizumab 10 mg/kg iv every 2 weeks versus
bevacizumab + paclitaxel versus paclitaxel
Martin bevacizumab, 2011	bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle versus control	patients with HER2-negative locally recurrent or metastatic breast cancer	open design
bevacizumab + taxanes versus taxanes
E2100 (Miller), 2007 NCT00028990	paclitaxel + bevacizumab 10 mg/kg iv every 2 weeks versus paclitaxel 90 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks	patients with metastatic breast cancer not previously treated	open
RIBBON-I (Robert) on top Tax or anthra, 2009	Taxanes or anthracyclines + bevacizumab 15 mg/kg iv every 3 weeks versus taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, o	irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
bevacizumav + CT versus CT alone
RIBBON-2 (Brufsky), 2009	addition of BV to chemotherapies used as second-line treatment for MBC versus chemo+placebo	second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer	open 19 countries
cediranib + fulvestrant versus fulvestrant
Hyams, NCT00454805	versus
enzastaurin + fulvestrant versus Fulvestrant
De Jong,	versus
Letrozole plus bevacizumab versus letrozole
Dickler (CALGB 40503°, 2015	versus
motesanib + paclitaxel versus paclitaxel
Martin (motesanib), 2011 NCT00356681	motesanib 125 mg orally once per da versus placebo	patients with untreated HER2-negative metastatic breast cancer	double-blind
sorafenib + gemcitabine or capecitabine versus gemcitabine or capecitabine alone
Schwartzberg, 2013 NCT00493636	sorafenib (400 mg, twice daily) versus placebo	patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab	double-blind
sorafenib + paclitaxel versus paclitaxel alone
Gradishar, 2013	paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily) versus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)	first-line therapy in patients with HER2-negative advanced breast cancer	double-blind

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags